title: Impact of interleukin-10 polymorphisms (-1082 and -3575) on the survival of patients with lymphoid neoplasms.
abstract: OBJECTIVE
  Single-nucleotide polymorphisms (SNP) in interleukin-10 (IL-10) genes can influence immune responses, which may affect the outcome of patients with lymphoid neoplasms. The aim of this study was to explore the association between polymorphisms of IL-10-(1082A>G) and IL-10-(3575T>A) with the overall survival in patients with lymphoid neoplasms.
  
  
  METHODS
  We analyzed two IL-10 SNP (-1082 and -3575) in 472 consecutive cases with lymphoid neoplasms. Genotypes were tested for association with overall survival and classical prognostic factors by multivariate analysis. Haplotype analysis was carried out using the haplostats package implemented in R software. The implications for survival of patients with lymphoma were evaluated using multivariate analysis.
  
  
  RESULTS
  Lymphoma patients with the IL-10-(3575T>A) genotype had a better overall survival (p= 0.002), as did the subgroup with non-Hodgkin's lymphoma (NHL) (p=0.05). Patients with the IL10(-1082GG) genotype had a better median overall survival (p=0.05). When both genotypes were included in a multivariate analysis, IL-10(-3575AA) genotype was the only independent prognostic factor for survival (HR=0.20, 95%CI 0.05-0.92). Patients with the IL-10(-1082) and (-3575) G-A/G-A diplotype had a longer overall survival (p=0.003) and this combination appeared to be an independent prognostic factor for survival (HR:0.26; 95%CI 0.08-0.83).
  
  
  CONCLUSIONS
  The IL-10(-3575A/A) genotype was identified as a marker of favorable survival. Because the IL-10(-1082) and (-3575) G-A/G-A diplotype was also identified as an indicator of longer survival, we cannot exclude the potential additive role of the IL-10(-1082GG) genotype. These results need to be replicated in larger series and examined in different NHL subtypes.
authors.affiliation: Department of Hematology, Institut Català d'Oncologia, Avda. Gran Via s/n, km 2.7, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. edomigo@iconcologia.net
authors.forename: Eva
authors.initials: E
authors.lastname: Domingo-Domènech
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Benavente
authors.forename: Eva
authors.initials: E
authors.lastname: González-Barca
authors.forename: Carlos
authors.initials: C
authors.lastname: Montalban
authors.forename: Josep
authors.initials: J
authors.lastname: Gumà
authors.forename: Ramón
authors.initials: R
authors.lastname: Bosch
authors.forename: Sophia S
authors.initials: SS
authors.lastname: Wang
authors.forename: Qing
authors.initials: Q
authors.lastname: Lan
authors.forename: Denise
authors.initials: D
authors.lastname: Whitby
authors.forename: Alberto
authors.initials: A
authors.lastname: Fernández de Sevilla
authors.forename: Nathaniel
authors.initials: N
authors.lastname: Rothman
authors.forename: Sílvia
authors.initials: S
authors.lastname: de Sanjosé
mesh_terms: D016022:Case-Control Studies; D005838:Genotype; D006239:Haplotypes; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D008223:Lymphoma / Q000175:diagnosis* / Q000235:genetics / Q000401:mortality; D015999:Multivariate Analysis; D020641:Polymorphism, Single Nucleotide; D011379:Prognosis; D013030:Spain; D015996:Survival Rate
chemical_list: D016753:Interleukin-10